Christopher Cano will lead Cellergy Pharma for the foreseeable future.
WILMINGTON — Cellergy Pharma Inc., a preclinical biotechnology firm developing novel therapies for severe allergic diseases, has named Christopher Cano as its new Chief Executive Officer.
The appointment marks a strategic shift as the Delaware-based company prepares to accelerate the development of its flagship CAR T-cell therapy.
“I am honored to begin leading Cellergy Pharma at this exciting, pivotal point in the company’s evolution, and look forward to accelerating the company’s strategy to advance this promising technology,” Cano said.
Cano brings over two decades of experience in pharmaceutical and biotech leadership, with a background in building early-stage companies and advancing cutting-edge treatments.
“There is a tremendous unmet need for patients suffering from severe uncontrolled asthma and severe food allergies., and CP-010 shows promise as a disease-modifying treatment that could alleviate, treat, and potentially cure these severe and life-threatening allergic reactions,” Cano said.
Prior to joining Cellergy Pharma, he served as Chief Operating Officer and Vice President of Business Development at TFF Pharmaceuticals and currently leads C2 Strategic Solutions, a business development advisory firm.
READ: Newark to launch new outage management system for electric customers
Cellergy Pharma is developing a “first-in-class” CAR T-cell therapy, CP-010, licensed from Nemours Children’s Health.
The experimental treatment targets membrane-bound IgE, aiming to eliminate the source of immunoglobulin E — the antibody responsible for triggering allergic reactions. If successful, CP-010 could represent a breakthrough in the treatment of severe asthma and food allergies.
“Chris’s leadership and operational experience will help propel the development of CP-101 into the next phase,” said Zhengyu “Mark” Ma, chief science officer of Cellergy Pharma. “His business development expertise will elevate Cellergy Pharma by expanding collaborative partnering efforts to aid our advances, growing the Cellergy Pharma team, and strengthening our pipeline of innovative programs.”
Ma developed CP-010 with support from Nemours Biomedical Research, a division of the Nemours Foundation focused on translational science.
Founded in Wilmington, Cellergy Pharma is positioning itself at the frontier of immunotherapy by adapting CAR T-cell technology—originally developed for cancer treatment—to target immune-related diseases.
The company’s patented EMPD and FcεRI chimeric antigen receptors are designed to selectively target the cells responsible for allergic responses.
Raised in Doylestown, Pennsylvania, Jarek earned a B.A. in journalism and a B.A. in political science from Temple University in 2021. After running CNN’s Michael Smerconish’s YouTube channel, Jarek became a reporter for the Bucks County Herald before joining Delaware LIVE News.
Jarek can be reached by email at jarek@dimgrey-peafowl-504880.hostingersite.com or by phone at (215) 450-9982. Follow him on Twitter @jarekrutz and on LinkedIn.
Related Posts:
Share this Post